QLi5 Therapeutics

QLi5 Therapeutics is a specialized biotechnology company focused on proteasome inhibitors, with core business in developing a new generation of non-covalent proteasome inhibitors and ADC payload platforms, targeting oncology, inflammation, and autoimmune diseases. The company is advancing a novel class of proteasome inhibitors that exhibit high selectivity and unique non-covalent binding properties.